Evidence map›Paper›PMID 39896473›Full record

ArticlebioRxiv : the preprint server for biology2025

Mapping cell-cell fusion at single-cell resolution.

Andrea L Gardner, Lan Zheng, Kennedy Howland, Andrew Saunders, Andrea Ramirez, Patrik Parker, Chisom Iloegbunam, Daylin Morgan, Tyler A Jost, Amy Brock

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrea L GardnerDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-5572-1647
Lan ZhengDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Kennedy HowlandDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0003-3433-9929
Andrew SaundersDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Andrea RamirezDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0009-0009-0284-4892
Patrik ParkerDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Chisom IloegbunamDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Daylin MorganDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-4218-2805
Tyler A JostDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-0338-1940
Amy BrockDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-8255-9024

Funding

Instability of Cancer Cell States in Tumor progression (ICCS)R01CA255536 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI BROCK, AMY, HUANG, SUI · 2021 to 2025
$2.5M
The Allee Effect in Tumor InitiationR01CA226258 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI BROCK, AMY, HUANG, SUI · 2018 to 2022
$2.3M
Using label-free Raman microscopy to predict therapeutic resistance of TNBC cellsU01CA253540 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI BROCK, AMY, YANKEELOV, THOMAS E · 2020 to 2024
$2.1M
A streamlined, high-throughput platform for validation of cancer antigen presentation and isolation of cancer antigen reactive T cellsR33CA256086 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BROCK, AMY, JIANG, NING JENNY · 2021 to 2023
$1.1M
Systems Approaches to Understanding the Impact of Cell-Cell Fusion on Therapeutic ResistanceF31CA268833 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI GARDNER, ANDREA L · 2023 to 2024
$80k
NCI NIH HHS F31 CA268833NCI NIH HHS R01 CA226258NCI NIH HHS R01 CA255536NCI NIH HHS R33 CA256086NCI NIH HHS U01 CA253540
6 · The paper itself

Abstract

Cell-cell fusion is a tightly controlled process in the human body known to be involved in fertilization, placental development, muscle growth, bone remodeling, and viral response. Fusion between cancer cells results first in a whole-genome doubled state, which may be followed by the generation of aneuploidies; these genomic alterations are known drivers of tumor evolution. The role of cell-cell fusion in cancer progression and treatment response has been understudied due to limited experimental systems for tracking and analyzing individual fusion events. To meet this need, we developed a molecular toolkit to map the origins and outcomes of individual cell fusion events within a tumor cell population. This platform, ClonMapper Duo ('CMDuo'), identifies cells that have undergone cell-cell fusion through a combination of reporter expression and engineered fluorescence-associated index sequences paired to randomly generated nucleotide barcodes. scRNA-seq of the indexed barcodes enables the mapping of each set of parental cells and fusion progeny throughout the cell population. In triple-negative breast cancer cells CMDuo uncovered subclonal transcriptomic hybridization and unveiled distinct cell-states which arise in direct consequence of homotypic cell-cell fusion. CMDuo is a platform that enables mapping of cell-cell fusion events in high-throughput single cell data and enables the study of cell fusion in disease progression and therapeutic response.

Identifiers

PMID39896473
PMCPMC11785005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.